| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
130,110,000 |
| Market
Cap: |
104.09(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.601 - $1.39 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 5.8 |
| Insider 3/6 Months : 6.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xtant Medical Holdings is a global medical technology company focused on the design, development, and commercialization of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in spine, deformity, and degenerative procedures. Co.'s products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Co. also processes and distributes sports allografts which are processed for anterior and posterior cruciate ligament repairs, milled spinal allografts which are comprised of cortical bone milled to desired shapes and dimensions, and allografts for multi-disciplinary applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
41,670 |
41,670 |
2,306,531 |
| Total Buy Value |
$0 |
$49,837 |
$49,837 |
$1,136,970 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
169,143 |
| Total Sell Value |
$0 |
$0 |
$0 |
$105,397 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
7 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orbimed Rof Ii Llc |
Director |
– • • |
2021-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
170,674 |
120,549 |
|
- |
|
| Peters Jeffrey J |
Director |
– • – |
2021-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
85,337 |
233,131 |
|
- |
|
| Brandt Kevin D |
Chief Commercial Officer |
• – – |
2021-08-15 |
4 |
D |
$1.20 |
$8,603 |
D/D |
(7,169) |
316,492 |
|
- |
|
| Brandt Kevin D |
Chief Commercial Officer |
• – – |
2021-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
162,109 |
323,661 |
|
- |
|
| Brandt Kevin D |
Chief Commercial Officer |
• – – |
2021-07-09 |
4 |
D |
$1.74 |
$15,312 |
D/D |
(8,800) |
161,552 |
|
- |
|
| Rizzo Matthew |
Director |
– • • |
2020-11-17 |
4 |
OE |
$0.01 |
$48,000 |
I/I |
4,800,000 |
17,036,720 |
|
- |
|
| Orbimed Rof Ii Llc |
Director |
– • • |
2020-11-17 |
4 |
OE |
$0.01 |
$48,000 |
I/I |
4,800,000 |
17,036,720 |
|
- |
|
| Eggenberg Michael |
Director |
– • • |
2020-11-17 |
4 |
OE |
$0.01 |
$48,000 |
I/I |
4,800,000 |
17,036,720 |
|
- |
|
| Browne Sean E |
President and Chief Executive |
• • – |
2020-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,468,859 |
1,797,903 |
|
- |
|
| Orbimed Rof Ii Llc |
Director |
– • • |
2020-10-01 |
4 |
A |
$1.07 |
$62,867,202 |
I/I |
58,754,394 |
15,300,688 |
|
- |
|
| Rizzo Matthew |
Director |
– • • |
2020-10-01 |
4 |
A |
$1.07 |
$62,867,202 |
I/I |
58,754,394 |
15,300,688 |
|
- |
|
| Eggenberg Michael |
Director |
– • • |
2020-10-01 |
4 |
A |
$1.07 |
$62,867,202 |
I/I |
58,754,394 |
15,300,688 |
|
- |
|
| Brandt Kevin D |
Chief Commercial Officer |
• – – |
2020-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
95,183 |
170,352 |
|
- |
|
| Jensen Greg |
VP, Finance and CFO |
• – – |
2020-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
95,183 |
129,081 |
|
- |
|
| Rizzo Matthew |
Director |
– • • |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
70,423 |
91,256 |
|
- |
|
| Mcnamara Robert |
Director |
– • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
116,197 |
146,057 |
|
- |
|
| Orbimed Rof Ii Llc |
Director |
– • • |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
I/I |
140,846 |
91,256 |
|
- |
|
| Bakewell John K |
Director |
– • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
116,197 |
147,794 |
|
- |
|
| Eggenberg Michael |
Director |
– • • |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
70,423 |
91,256 |
|
- |
|
| Peters Jeffrey J |
Director |
– • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
116,197 |
147,794 |
|
- |
|
| Rizzo Matthew |
Director |
– • • |
2019-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
20,833 |
20,833 |
|
- |
|
| Eggenberg Michael |
Director |
– • • |
2019-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
20,833 |
20,833 |
|
- |
|
| Orbimed Rof Ii Llc |
Director |
– • • |
2019-10-30 |
4 |
A |
$0.00 |
$0 |
I/I |
41,666 |
20,833 |
|
- |
|
| Browne Sean E |
President and CEO |
• – – |
2019-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
329,044 |
329,044 |
|
- |
|
| Brandt Kevin D |
Chief Commercial Officer |
• – – |
2019-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
35,169 |
75,169 |
|
- |
|
145 Records found
|
|
Page 3 of 6 |
|
|
0.01 (1.27%) 
